Generic Name for REVATIO
Sildenafil citrate 20mg; tabs.
Legal Classification:
Rx
Pharmacological Class for REVATIO
Phosphodiesterase type 5 inhibitor (cGMP-specific).
Manufacturer of REVATIO
Pfizer Inc.
|
Indications for REVATIO
Pulmonary arterial hypertension (PAH) (WHO Group I) to improve exercise ability and delay clinical worsening.
Adult dose for REVATIO
20mg three times daily; separate dosing by 4–6 hrs (see Interactions).
Children's dosing for REVATIO
Not recommended.
Also:
Contraindications for REVATIO
Concomitant organic nitrates.
Warnings/Precautions for REVATIO
Pulmonary veno-occlusive disease: not recommended. PAH secondary to sickle cell anemia. Cardiovascular disease (eg, MI, stroke, or life-threatening arrhythmias within 6 months; BP<90/50 or >170/110; coronary artery disease, unstable angina, LV outflow obstruction, fluid depletion, impaired autonomic regulation of BP). Retinitis pigmentosa. Anatomical penile deformation. Predisposition to priapism. Severe renal or hepatic impairment. Active peptic ulcer. Bleeding disorders. Elderly. Pregnancy (Cat.B). Nursing mothers.
Interactions for REVATIO
See Contraindications. Hypotension with nitrates. Concomitant potent CYP3A4 inhibitors (eg, ketoconazole, itraconazole, ritonavir): not recommended. Potentiated by inhibitors of CY3A4 or CYP2C9, or cimetidine; may need dose adjustment. Antagonized by CYP3A4 inducers (eg, rifampin), bosentan; may need to adjust dose. Concomitant α-blockers (eg, doxazosin) may cause symptomatic hypotension. Potentiates bleeding risk with Vit. K antagonists. Concomitant Viagra or other PDE5 inhibitors: not recommended.
Adverse Reactions for REVATIO
Epistaxis, headache, GI upset, flushing, insomnia, erythema, dyspnea worsened, rhinitis, sinusitis, myalgia, pyrexia, paresthesia; hypotension, vision or hearing loss, priapism.
How is REVATIO supplied?
Tabs—90
Single-use vial—1